Incyte misses quarterly profit on weak sales of lead drug
April 30 (Reuters) -Incyte Corp INCY.O on Tuesday reported first-quarter profit below Wall Street estimates on weak sales of its blood cancer drug Jakafi, sending its shares down 2.4%.
The company is working on strengthening its pipeline to counter competition from newly approved drugs, which could impact sales of Jakafi, the company's biggest-selling drug, as it nears the loss of exclusivity later this decade.
During the first quarter, the Delaware-based company gained worldwide exclusive global rights for Monjuvi, approved by the FDA for the treatment of certain kinds of blood cancer, from MorphoSys AG MORG.DE.
In April, the company also announced it had entered into a definitive agreement to acquire Escient Pharmaceuticals, a clinical-stage company involved in the development of treatment of various skin diseases.
Sales of Jakafi were down 1% to $571.8 million for the quarter, compared with analysts' expectations of $615.80 million, according to LSEG data.
Chief Executive Officer Hervé Hoppenot said, "As anticipated, the revenue growth during the quarter was offset by an inventory drawdown for Jakafi and the typical first-quarter net pricing dynamics."
Total revenue for the reported quarter came in at $880.90 million, below estimates of $923.6 million. Revenue generated by the drugmaker in the first quarter from royalties was $126 million, up 9% from a year earlier.
Incyte earns product royalty revenues from Novartis AG NOVN.S for the commercialization of Jakafi outside the United States and from Eli Lilly LLY.N for Olumiant for the treatment of rheumatoid arthritis.
Opzelura, which is approved in the U.S. to treat vitiligo and mild-to-moderate atopic dermatitis, recorded revenue of $85.7 million, up 52% from a year earlier. Analysts were expecting a revenue of $66.60 million.
Excluding items, the U.S. drugmaker earned 64 cents per share in the quarter, missing estimates of 84 cents per share.
Reporting by Vaibhav Sadhamta; Editing by Vijay Kishore
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
